CD70.CAR NK Cells
Phase 2Cell therapy
CD70.CAR NK Cells is one of 17 small molecule programs targeting Large B-cell Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Golcadomide
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 2
Zynlonta
Akero TherapeuticsPhase 2
Fabhalta
BBellicum Pharmaceuticals
Phase 2
Lymphodepleting Chemotherapy
BBeijing Biotech
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD70.CAR NK Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- MM.D. Anderson Cancer Center